<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620875</url>
  </required_header>
  <id_info>
    <org_study_id>2021-06630-01</org_study_id>
    <nct_id>NCT05620875</nct_id>
  </id_info>
  <brief_title>The Association Between Delivered Oxygen and Cerebral Impact During the Use of Cardiopulmonary Bypass.</brief_title>
  <official_title>The Association Between Delivered Oxygen and Cerebral Impact During the Use of Cardiopulmonary Bypass.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the connection between delivered oxygen index and cerebral impact with COx&#xD;
      (cerebral oximetry index) och cerebral injury markers during the routine use of&#xD;
      cardiopulmonary bypass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research subjects are to be treated with CPB with according to local standards (perfusion&#xD;
      index 2.4 x body surface area). While measuring impact on cerebral autoregulation with the&#xD;
      aid of Near InfraRed Spectroscopy (NIRS) and brain injury markers in blood, research subjects&#xD;
      depending on initial hemoglobin value, will divide into two subgroups: one with DO2I of &gt;280&#xD;
      ml/min/m2, and one with DO2I of &lt;280 ml/min/m2.&#xD;
&#xD;
      DO2I will during CPB be calculated using the patient data monitoring system Metavision.&#xD;
&#xD;
      With a correlation analysis between NIRS and MAP (mean arterial pressure) a COx (Cerebral&#xD;
      Oxymetry Index) r-value can indicate impact on cerebral autoregulation with values &gt;0.3 - 0.5&#xD;
      during use of CPB 4.&#xD;
&#xD;
      Brain injury markers (Tau, Glial Fibrillary Acidic Protein (GFAP), Neurospecific Enolase&#xD;
      (NSE)) are collected during 5 occasions during the first 24 hours and then once per day for 4&#xD;
      days, as well as markers for AKI (S-Creatinine) in some extent.&#xD;
&#xD;
      Registrations during the intensive care regarding delirium, stroke or other neurological&#xD;
      impact will also be included in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 14, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Days</target_duration>
  <primary_outcome>
    <measure>COx</measure>
    <time_frame>24 hours</time_frame>
    <description>COx (Cerebral Oximetry Index; correlation between rSO2 values (INVOS) and mean artery pressure) that indicated impact on cerebral autoregulation on DO2 index values below set limits of 280 ml/m2/min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain injury markers; tau, GFAP, NSE</measure>
    <time_frame>96 hours</time_frame>
    <description>Brain injury markers that indicate cerebral neuronal damage on DO2 index values below set limits of 280 ml/m2/min.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cardiac; Arteriosclerosis</condition>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Group with DO2i &lt;280 ml/min/m2 during cardiopulmonary bypass</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with DO2i &gt;280 ml/min/m2 during cardiopulmonary bypass</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cerebral injury markers</intervention_name>
    <description>Blood tests at given time points perioperatively.</description>
    <arm_group_label>Group with DO2i &lt;280 ml/min/m2 during cardiopulmonary bypass</arm_group_label>
    <arm_group_label>Group with DO2i &gt;280 ml/min/m2 during cardiopulmonary bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cerebral oximetry index</intervention_name>
    <description>Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy</description>
    <arm_group_label>Group with DO2i &lt;280 ml/min/m2 during cardiopulmonary bypass</arm_group_label>
    <arm_group_label>Group with DO2i &gt;280 ml/min/m2 during cardiopulmonary bypass</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebral injury markers in blood plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        120 research subjects scheduled for coronary arterial bypass grafting surgery and/or aortic&#xD;
        valve replacement in Uppsala University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for CABG and/or AVR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Former diagnosed neurological insults, carotid stenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Henrik Grinnemo, Adj. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Arthursson, PhD student</last_name>
    <phone>+46735247762</phone>
    <email>henrik.arthursson@surgsci.uu.se</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

